STORY FROM: Drugs & Medical Devices

FDA Says Trial Results Show Gout Drug Uloric Poses Increased Risk of Heart-Related Death

WASHINGTON, D.C. — The Food and Drug Administration has issued an alert that preliminary results from a safety clinical trial show an increased risk of heart-related death with Takeda Pharmaceuticals’ gout drug Uloric (febuxostat) compared to its competitor drug, allopurinol.

In a Nov. 14 Drug Safety Communication, the agency said it required Takeda to conduct the safety study when Uloric was approved in 2009. Once Takeda receives the final results, the FDA will conduct a comprehensive review and update the public with any new information, the alert says.

“The safety trial was conducted in over 6,000 patients with gout treated ...



Registered User Login

Username

Password

True